In order to determine whether FUNDC2 suppresses MFN1 GTP-binding in human HCC, we first profiled the expression of FUNDC2 in 20 HCC samples by quantitative RT-PCR (Supplementary Fig. 6c). Here, FUNDC2 is linked to hepatocellular carcinoma.